Critical Comparison: Dyne Therapeutics (NASDAQ:DYN) versus Y-mAbs Therapeutics (NASDAQ:YMAB)

Dyne Therapeutics (NASDAQ:DYN) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Valuation & Earnings

This table compares Dyne Therapeutics and Y-mAbs Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$235.94 million	($3.94)	-6.30
Y-mAbs Therapeutics	$84.82 million	7.80	-$21.43 million	($0.49)	-30.84

Y-mAbs Therapeutics has higher revenue and earnings than Dyne Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Dyne Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dyne Therapeutics and Y-mAbs Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	0	0	6	1	3.14
Y-mAbs Therapeutics	2	0	4	0	2.33

Dyne Therapeutics presently has a consensus target price of $37.43, suggesting a potential upside of 50.80%. Y-mAbs Therapeutics has a consensus target price of $16.57, suggesting a potential upside of 9.67%. Given Dyne Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Y-mAbs Therapeutics.

Institutional & Insider Ownership

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by insiders. Comparatively, 21.5% of Y-mAbs Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Dyne Therapeutics and Y-mAbs Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-136.35%	-103.67%
Y-mAbs Therapeutics	-25.26%	-20.72%	-16.28%

Summary

Dyne Therapeutics beats Y-mAbs Therapeutics on 8 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.